These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854 [TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. Raza S; Safyan RA; Lentzsch S Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976 [TBL] [Abstract][Full Text] [Related]
15. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Sonneveld P; De Wit E; Moreau P Crit Rev Oncol Hematol; 2017 Apr; 112():153-170. PubMed ID: 28325256 [TBL] [Abstract][Full Text] [Related]
16. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data. Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833 [TBL] [Abstract][Full Text] [Related]
17. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Zangari M; Fink L; Zhan F; Tricot G Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928 [TBL] [Abstract][Full Text] [Related]